Adipose-derived stromal vascular fraction cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05699161 (ClinicalTrials.gov) | October 14, 2021 | 7/12/2022 | Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson | Treatment of Parkinson Disease With Transplantation of SVF Cells of Adipose Origin: Safety and Exploratory Efficacy Study | Idiopathic Parkinson Disease;Parkinson's Disease and Parkinsonism | Genetic: Adipose-derived stromal vascular fraction cells | Samuel Vilchez, PhD | Wake Forest University;Ministerio de Salud, Nicaragua;GID BIO, Inc.;National Autonomous University of Nicaragua | Completed | 18 Years | 80 Years | All | 10 | Phase 1/Phase 2 | Nicaragua |